These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 778447)

  • 1. Studies on the properties of a streptococcal preparation OK-432 (NSC-B116209) as an immunopotentiator. I. Activation of serum complement components and peritoneal exudate cells by group A streptococcus.
    Sakai S; Ryoyama K; Koshimura S; Migita S
    Jpn J Exp Med; 1976 Apr; 46(2):123-33. PubMed ID: 778447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.
    Oshimi K; Kano S; Takaku F; Okumura K
    J Natl Cancer Inst; 1980 Dec; 65(6):1265-9. PubMed ID: 7001124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
    Kataoka T; Oh-hashi F
    Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced antitumor and immune-adjuvant activities of the sub-cellular fractions from Group A Streptococcus.
    Ryoyama K; Natsuume-Sakai S; Hirota H; Koshimura S
    Jpn J Exp Med; 1981 Dec; 51(6):335-44. PubMed ID: 7040746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Production of a cytotoxic factor in mouse peritoneal fluid by OK-432, a streptococcal preparation].
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 May; 13(5):1905-10. PubMed ID: 3707150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T; Okamoto M; Tano T; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Akira S; Sato M
    J Immunother; 2006; 29(2):143-50. PubMed ID: 16531815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xenoantisera against a murine T cell tumor product cross-react with immunoglobulin Fab determinants.
    Mackel AM; Craddock GR; Warr GW; DeLuca D; Marchalonis JJ
    J Immunol; 1983 Sep; 131(3):1582-90. PubMed ID: 6350458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human T-cell heterogeneity as delineated with a specific human thymus lymphocyte antiserum. In vitro effects on mitogen response mixed leukocyte culture, cell-mediated lymphocytotoxicity, and lymphokine production.
    Woody JN; Ahmed A; Knudsen RC; Strong DM; Sell KW
    J Clin Invest; 1975 May; 55(5):956-66. PubMed ID: 1091657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of streptococcal acid glycoprotein produced by Streptococcus pyogenes Su.
    Kanaoka M; Fukita Y; Taya K; Kawanaka C; Negoro T; Agui H
    Jpn J Cancer Res; 1987 Dec; 78(12):1409-14. PubMed ID: 3123442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
    Kataoka T; Oh-hashi F; Sakurai Y
    Cancer Res; 1979 Jul; 39(7 Pt 1):2807-10. PubMed ID: 445486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.